IQVIA (NYSE:IQV) Given New $286.00 Price Target at Truist Financial

IQVIA (NYSE:IQV) had its price objective lowered by Truist Financial from $300.00 to $286.00 in a research report report published on Monday morning, Benzinga reports. Truist Financial currently has a buy rating on the medical research company’s stock.

Several other brokerages have also commented on IQV. Barclays lifted their price objective on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday. They set a “buy” rating and a $276.00 target price for the company. Finally, Morgan Stanley boosted their price objective on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $267.87.

IQVIA Trading Up 0.0 %

IQVIA stock opened at $233.06 on Monday. IQVIA has a one year low of $167.42 and a one year high of $261.73. The business’s fifty day moving average is $239.14 and its 200 day moving average is $231.33. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market capitalization of $42.46 billion, a PE ratio of 31.84, a price-to-earnings-growth ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period in the previous year, the business posted $2.22 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, sell-side analysts predict that IQVIA will post 10.25 EPS for the current year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of the business. Centaurus Financial Inc. purchased a new position in IQVIA in the fourth quarter worth about $169,000. ICA Group Wealth Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at approximately $77,000. PNC Financial Services Group Inc. lifted its position in IQVIA by 4.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 43,380 shares of the medical research company’s stock worth $10,037,000 after buying an additional 1,943 shares during the last quarter. HighPoint Advisor Group LLC purchased a new position in IQVIA during the fourth quarter worth $404,000. Finally, Nomura Holdings Inc. bought a new position in IQVIA during the fourth quarter valued at $857,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.